

GENERAL INFORMATION

CONGRESS VENUE

Royal Hotel Carlton
Via Montebello, 8
40121 Bologna, Italy
www.royalhotelcarltonbologna.com

OFFICIAL LANGUAGE

English

REGISTRATION

Registration is free and it is available
at www.ercongressi.it - section
“I nostri congressi/anno 2026”

CME

An application for Italian CME credits has been
made as follows:

- Provider Studio ER Congressi SRL: ID 828- 476838
- **No. 4,9 CME credits** for physicians
(disciplines: hematology, oncology)
- Educational objective: “guidelines-protocols-
procedures”

SCIENTIFIC SECRETARIAT

Antonio Curti
IRCCS Azienda Ospedaliero-Universitaria di Bologna,
Istituto di Ematologia “Seràgnoli”, Bologna

ORGANIZING SECRETARIAT

Studio E.R. Congressi
Via De' Poeti 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559
E-mail: ercongressi@ercongressi.it
www.ercongressi.it



ER Congressi

With the unrestricted educational grant of

Johnson & Johnson



Auspices

SIE – Società Italiana di Ematologia
SIES – Società Italiana di Ematologia Sperimentale

2nd BOLOGNA WORKSHOP on IMMUNOTHERAPY FOR ACUTE MYELOID LEUKEMIA

Bologna, Royal Hotel Carlton
September 29-30, 2026



14.00 Welcome

M. Seri (Bologna), P.L. Zinzani (Bologna)

14.10 Rationale and goals of the workshop

A. Curti (Bologna)

14.20 Lecture

Chairman: *P.L. Zinzani (Bologna)*

Clonal evolution in myeloid neoplasms and inflammatory stromal remodeling: implications for immunotherapy

M.H.G.P. Raaijmakers (Rotterdam, The Netherlands)

SESSION 1

INSIDE OUT: HOW CELL-INTRINSIC FEATURES OUTBREAK AML IMMUNE MICROENVIRONMENT

Chairmen: *A. Curti (Bologna), F. Pane (Napoli)*

14.50 Leukemia hematopoietic hierarchies and differentiation state

S.C. Renders (Heidelberg, Germany)

15.10 AML genomic landscape: focus on IDH1 and FLT3

J. Nanni (Bologna)

15.30 Leukemia epigenetic remodelling: the lesson of allogeneic stem cell transplantation

L.A.E. Vago (Milan)

15.50 Epithelial-to-mesenchymal transition

S. Sangaletti (Milan)

16.10 Leukemic cell metabolic profile

G. Simonetti (Meldola-FC)

16.30 Coffee break

SESSION 2

WHICH ARE THE HALLMARKS OF AML IMMUNE MICROENVIRONMENT?

Chairmen: *A. Curti (Bologna), S. Rutella (Sheffield, UK)*

16.50 Inflammation and T-cell dysfunctionality

S. Rutella (Sheffield, UK)

17.10 Reprogramming the cytotoxic architecture of NK cells to sustain functional persistence

K.J. Malmberg (Oslo, Norway)

17.30 Bone marrow immune cells aggregation

O. Heidenreich (Utrecht, The Netherlands)

17.50 Immune dysregulation dominance and poor outcome: when MDS looks like AML

S. Kordasti (London, UK)

18.10 Aging and immune bone marrow microenvironment

C. Waskow (Jena, Germany)

8.45 Introduction of the second day of scientific works

SESSION 3

SO WHAT? HOW TO MOVE A STEP FORWARD INTO THE CLINICS

Chairmen: *A. Curti (Bologna), A. Venditti (Roma)*

9.00 Dendritic cell immunotherapy in myeloid leukemia

B.T. Gjertsen (Bergen, Norway)

9.20 AML-directed CAR-T cell therapies: where we stand

M. Subklewe (Munich, Germany)

9.40 Combination backbone for immunotherapies: focus on Aza-Ven

A. Curti (Bologna)

10.00 Menin inhibition: immunological effects and implications for future immunotherapies

- **NPM1 and immune microenvironment**

M.P. Martelli (Perugia)

- **Menin inhibitors**

C. Papayannidis (Bologna)

10.45 Coffee break

SESSION 4

NOVEL TOOLS, PARADIGMS AND PERSPECTIVES: IN SEARCH OF IMMUNOLOGICAL BIOMARKERS

Chairmen: *A. Curti (Bologna), D. Forte (Bologna)*

11.00 Spatial omics

J.C. Schroeder (Tübingen, Germany)

11.20 Amino acids and tryptophan metabolites

C.A. Opitz (Heidelberg, Germany)

11.40 3D models

U. Riekstina (Riga, Latvia)

12.00 Extracellular vesicles

D. Forte (Bologna)

12.20 Real-time immunometabolism

R.J. Argüello (Marseille, France)

12.40 Final discussion and concluding remarks

A. Curti (Bologna)

